- Home
- CMBM vs BLRX Comparison
CMBM vs BLRX Comparison
Compare CMBM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMBM | BLRX |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 12.9M |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | CMBM | BLRX |
|---|---|---|
| Price | $1.58 | $2.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.4M | 27.4K |
| Earning Date | 02-19-2026 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $172,215,000.00 | $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.23 | $2.30 |
| 52 Week High | $6.80 | $14.70 |
Technical Indicators
Market Signals| Indicator | CMBM | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.73 | 41.09 |
| Support Level | $1.41 | $2.87 |
| Resistance Level | $1.69 | $3.10 |
| Average True Range (ATR) | 0.20 | 0.18 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 22.22 | 24.14 |
Price Performance
Historical ComparisonAbout CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.